Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies
Journal of Clinical Medicine · 10 authors, 7 centres
AI SUMMARY
FIDELITY 100%
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review summarizes nanotechnology-based drug delivery systems, such as nanoparticles and hydrogels, as potential advances for treating primary open-angle glaucoma. The central result is that these technologies may improve drug bioavailability and patient compliance compared to conventional eye drops.
Full summary
708 CHARS
The authors describe the pathophysiology of POAG, focusing on elevated intraocular pressure (IOP) as a key modifiable risk factor. They outline conventional pharmacological treatments and their limitations, such as low bioavailability and poor patient adherence due to frequent dosing. The review details various nanocarriers under preclinical investigation—including hydrogels, liposomes, niosomes, nanoemulsions, and nanocrystals—highlighting their potential for controlled drug release, enhanced ocular penetration, and reduced systemic side effects. The authors conclude that while nanotechnology holds significant promise for revolutionizing glaucoma therapy, challenges remain for clinical translation.